Targeted drugs for breast and lung cancer could be used together to overcome resistance to treatment in several different tumour types, a new study shows. Scientists discovered that when the breast cancer drug palbociclib was combined with the lung cancer drug crizotinib, the two-drug combination was significantly more effective against cancer cells in the laboratory than either drug used on its own.